Caffeine based measures of CYP1A2 activity correlate with oral clearance of tacrine in patients with Alzheimer's disease.

British journal of clinical pharmacology1998Fontana RJ, deVries TM, Woolf TF, et al.

Study designRandomized controlled trial

SubjectHuman

Record checks

Study design: Randomized controlled trial
Subject: Human
Publication year: 1998
Source: doi.org
Abstract display: Not reproduced here
Publication status: Active
Status checked: 17 Aug 2026
Collected: 3 Aug 2026
Freshness: Current
Review stage: Automated
Record status: Published

How to read this record →

Abstract

cc by 以外（cc by-nc / cc by-nc-nd / NONE 等）は抄録を再掲しない。DOI/PMID へのリンクのみ表示する。

MeSH

Administration, OralAgedAged, 80 and overAlzheimer DiseaseCaffeineCholinesterase InhibitorsCytochrome P-450 CYP1A2FemaleHumansMaleMiddle AgedPhosphodiesterase InhibitorsPredictive Value of TestsTacrine

DOI 10.1046/j.1365-2125.1998.00776.x

PMID 9764962

View source →